169463-44-9Relevant articles and documents
Synthesis and evaluation of a series of C5′-substituted duocarmycin SA analogs
Robertson, William M.,Kastrinsky, David B.,Hwang, Inkyu,Boger, Dale L.
, p. 2722 - 2725 (2011/07/06)
The synthesis and evaluation of a key series of analogs of duocarmycin SA, bearing a single substituent at the C5′ position of the DNA binding subunit, are described.
CBI analogues of the duocarmycins and CC-1065
-
Page 23-24, (2010/02/10)
An extensive series of CBI analogues of the duocarmycins and CC-1065 exploring substituent effects within the first indole DNA binding subunit is detailed. In general, substitution at the indole C5 position led to cytotoxic potency enhancements that can be ≧1000-fold providing simplified analogues containing a single DNA binding subunit that are more potent (IC50=2-3 pM) than CBI-TMI, duocarmycin SA, or CC-1065. The increases in cytotoxicity correlate well with accompanying increases in the rate and efficiency of DNA alkylation. This effect is more pronounced with the CBI versus DSA or CPI based analogues. Moreover, this effect is largely insensitive to the electronic character of the C5 substituent but is sensitive to the size, rigid length, and shape (sp, sp2, sp3 hybridization) of this substituent consistent with expectation that the impact is due simply to its presence.
Novel 3,4-Dihydroquinolin-2(1H)-one inhibitors of human glycogen phosphorylase a
Rosauer, Keith G.,Ogawa, Anthony K.,Willoughby, Chris A.,Ellsworth, Kenneth P.,Geissler, Wayne M.,Myers, Robert W.,Deng, Qiaolin,Chapman, Kevin T.,Harris, Georgianna,Moller, David E.
, p. 4385 - 4388 (2007/10/03)
The preparation of a series of substituted indoles coupled to six- and seven-membered cyclic lactams is described and their role as human glycogen phosphorylase a inhibitors discussed. The SAR of the indole moiety and lactam ring are presented.
Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
-
, (2008/06/13)
Compounds of the formula I: and their compositions are useful as glycogen phosphorylase inhibitors.
Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides
-
, (2008/06/13)
Processes and intermediates for preparing compounds of Formula (I).
Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
-
, (2008/06/13)
PCT No. PCT/IB95/00442 Sec. 371 Date Dec. 2, 1997 Sec. 102(e) Date Dec. 2, 1997 PCT Filed Jun. 6, 1995 PCT Pub. No. WO96/39384 PCT Pub. Date Dec. 12, 1996Compounds of Formula (1) wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR8R9 or C(O)R12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.
5,6-Bicyclic glycoprotein IIb IIIa antagonists useful in inhibition of platelet aggregation
-
, (2008/06/13)
This invention relates to 5,6 fused ring bicyclic compounds inclusive of indoles, benzofurans, and benzothiophenes, and corresponding to the formula (I) substituted with both basic (B) and acidic (A) functionality, which are useful in inhibition of platelet aggregation.
